
FDA approves treatments for heart failure caused by rare disease
(HealthDay)—Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules have been approved to treat adults with cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM), the U.S. Food and Drug Administration ...
May 7, 2019
0
0